WELL Health vs. CloudMD: Which TSX Growth Stock Should You Buy Right Now?

WELL Health and CloudMD are two health-tech stocks that have the potential to deliver outsized gains to long-term investors.

| More on:
healthcare pharma

Image source: Getty Images

In the past decade, growth stocks have crushed the broader indices, driven by a spectacular bull run in the equity markets. While the COVID-19 pandemic decimated the stock market in early 2020, the snap-back rally pushed major indices to record highs, primarily due to growth stocks in the technology space.

The ongoing pandemic has also acted as a tailwind for several companies, such as WELL Health (TSX:WELL) and CloudMD (TSXV:DOC). The shift towards telehealth solutions has accelerated in the last 15 months due to the need for social distancing and economic lockdowns imposed by several countries. However, this trend is likely to continue in 2021 and beyond, making WELL Health and CloudMD solid long-term bets.

WELL Health has gained 8,700% since IPO

WELL Health has been on an absolute tear since its IPO five years back. WELL stock has returned a staggering 8,700% after it went public, which means a $1,000 investment just after its IPO would be worth close to $88,000 today.

This astonishing growth has been supported by a strong uptick in sales and improvement in profit margins. WELL Health has increased sales from $5.9 million in 2018 to $50.24 million in 2020. Comparatively, its operating loss stood at $2.09 million in 2018, or 35.4% of sales, while in 2020, the company reported an operating loss of $10.4 million, or 20.7% of sales.

WELL Health has aggressively acquired companies in the last two years that have contributed to its top-line growth. After we account for its recent acquisitions of CRH Medical and MyHealth, WELL’s combined pro forma sales will be close to $400 million, while its EBITDA would be $100 million on a run-rate basis.

Analysts tracking WELL stock forecast 2021 sales to rise by 427% to $265 million and by 60% to $423 million in 2022. Its bottom line is also expected to improve from a loss per share of $0.03 in 2020 to earnings per share of $0.06.

WELL Health stock is valued at a price-to-2022-sales multiple of 4.6, which is really cheap considering its growth estimates.

CloudMD stock is valued at a market cap of $535 million

Shares of CloudMD have gained 144% since its IPO in late 2017. However, CMD stock is currently trading 27% below its record high, providing investors an opportunity to buy the dip. In the first quarter of 2021, CloudMD sales were up 187% year over year at $8.8 million. It ended the quarter with a gross margin of 41%, which was attributed to a strong revenue mix.

Similar to WELL Health, CloudMD has also grown inorganically, and the company closed five acquisitions in the March quarter, adding $13 million in annualized sales.

CloudMD has experienced early adoption in its Enterprise Health Solutions division, which has bagged $5 million in new multi-year contracts in the March quarter.

During the earnings call, company CEO Dr. Essam Hamza said, “CloudMD already has a revenue run rate of over $120 million, and through highly profitable acquisitions coupled with organic growth and realization of cost synergies, we expect to be profitable in the second half of 2021.”

The final takeaway

Both WELL Health and CloudMD are exciting bets for investors looking to beat the market. However, if I have to choose a winner, it would have to be WELL Health given its larger revenue base and lower valuation metrics.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Tech Stocks

Lady holding mobile phone and shopping bags
Tech Stocks

The Ultimate Growth Stock to Buy With $1,000 Right Now 

Here's why Shopify (TSX:SHOP) could be the ultimate growth stock long-term investors want to consider at this current point in…

Read more »

Hands shaking over a business deal
Tech Stocks

Meet the Growth Stock I Can’t Stop Buying This Year

Topicus stock (TSXV:TOI) has been a top growth stock this year, with strong finances, a stable acquisition strategy, and more…

Read more »

grow dividends
Tech Stocks

Celestica Stock Is up 44% Since Earnings: What Investors Need to Know

Celestica continues to benefit from strong demand and production efficiencies, yet the stock remains undervalued.

Read more »

healthcare pharma
Tech Stocks

What’s Going on With WELL Health Stock?

WELL stock (TSX:WELL) made strong moves once again, with record earnings and even higher guidance for 2024.

Read more »

A shopper makes purchases from an online store.
Tech Stocks

3 Reasons to Buy Shopify Stock Right Now

Based on these three top reasons, Shopify (TSX:SHOP) stock appears undervalued to buy right now.

Read more »

stock research, analyze data
Tech Stocks

What’s Going on With Lightspeed Stock?

Lightspeed (TSX:LSPD) stock has been climbing once more but is still far from its three-digit share price. So, is it…

Read more »

Target. Stand out from the crowd
Tech Stocks

Missed Out on Nvidia Stock (Again)? Buy Descartes Instead

Nvidia (NASDAQ:NVDA) stock soared yet again after earnings, passing the four-digit mark. But with shares so high, maybe this option…

Read more »

Group of people network together with connected devices
Tech Stocks

This Is the Best Overlooked AI Stock on the TSX Today

This AI stock has been a top growing in the last while, but remains overlooked despite its strong portfolio and…

Read more »